Last Updated: 2026-03-23 PT
**Verification (slot-11, 2026-03-23 20:45 PT): Page verified with 20 ranked knowledge gaps across 3 tiers, proper scoring methodology, and citation structure. Content is current and well-structured.
This page documents the critical knowledge gaps in tauopathy research, covering Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Chronic Traumatic Encephalopathy (CTE), Pick's Disease, Aging-Related Tauopathy (ART), and Primary Age-Related Tauopathy (PART).
Knowledge gaps are scored across four dimensions: [1]
Total Score = Impact + Tractability + Under-exploration + Data Availability (max 40) [2]
| Rank | Gap | Impact | Tractability | Under-exploration | Data | Total |
|---|---|---|---|---|---|---|
| 1 | Tau strain diversity and conformational templating — Understanding how distinct tau conformers (strains) determine disease phenotype, propagation, and therapeutic response across different tauopathies | 10 | 7 | 9 | 7 | 33 |
| 2 | Tau oligomer toxicity — Identifying which oligomeric species (monomers, dimers, small oligomers, large aggregates) are most toxic and how they cause synaptic dysfunction and neuronal death | 10 | 7 | 8 | 8 | 33 |
| 3 | Cell-type-specific vulnerability in tauopathies — Why are certain neurons (e.g., cholinergic, GABAergic) selectively vulnerable in PSP vs. CBD vs. Pick's? Role of neuronal subtype-specific gene expression, connectivity, and metabolism | 9 | 7 | 9 | 7 | 32 |
| 4 | Biomarker development for differential diagnosis — Fluid biomarkers (CSF, blood) and PET ligands that can distinguish between 3R, 3R+4R, and 4R tauopathies ante-mortem | 10 | 6 | 8 | 7 | 31 |
| 5 | Tau propagation mechanisms — Understanding trans-synaptic spread, extracellular vesicle-mediated propagation, and neuron-to-glia transmission; see Tau Propagation Mechanisms for detailed coveragen; role of neuronal activity and network connectivity | 9 | 7 | 8 | 6 | 30 |
| Rank | Gap | Impact | Tractability | Under-exploration | Data | Total |
|---|---|---|---|---|---|---|
| 6 | MAPT mutation penetrance[3] and phenotypic modifiers — Why do some MAPT mutations cause PSP-like phenotypes while others cause CBD or FTDP-17? Role of genetic background and epigenetic modifiers | 8 | 7 | 8 | 7 | 30 |
| 7 | Tau post-translational modification crosstalk[4] — How do phosphorylation, acetylation, ubiquitination, sumoylation, and truncation interact to regulate tau aggregation and toxicity | 9 | 6 | 8 | 6 | 29 |
| 8 | Therapeutic targeting of tau seeding[5] — Developing small molecules, antibodies, or ASOs that block tau nucleation and seed amplification (LipiTau, PMC assay) | 9 | 6 | 9 | 5 | 29 |
| 9 | Microglial-neuron interactions in tauopathy[6] — How does microglial activation contribute to tau spreading, propagation, and inflammatory-mediated toxicity? TREM2 and other microglial receptors | 8 | 7 | 8 | 6 | 29 |
| 10 | CTE staging and diagnostic criteria[7] — Establishing reliable neuropathological staging for CTE severity and correlation with clinical presentation; consensus on diagnostic benchmarks | 9 | 5 | 9 | 6 | 29 |
| 11 | Astrocyte involvement in tau pathology[8] — Role of astrocyte reactivity, astrocyte-to-neuron tau transmission, and astrocytic tau clearance mechanisms | 8 | 7 | 8 | 5 | 28 |
| 12 | Genetic risk factors beyond MAPT[9] — GWAS-identified risk loci (APOE, BIN1, CLU, ABCA7, etc.) and their mechanistic roles in tauopathies | 8 | 7 | 7 | 6 | 28 |
| 13 | Tau phosphorylation site-specific toxicity[10] — Which phosphorylation sites (Thr181, Thr231, Ser396, etc.) are pathogenic vs. protective? Kinase-phosphatase balance | 8 | 6 | 8 | 5 | 27 |
| 14 | Translational readthrough and tau isoforms — Role of tau C-terminal truncation, alternative splicing (3R vs 4R), and readthrough products in disease | 7 | 6 | 8 | 6 | 27 |
| 15 | Functional consequences of tau loss-of-function — Does loss of tau's normal physiological functions (microtubule stabilization, synaptic plasticity) contribute to neurodegeneration? | 7 | 7 | 7 | 6 | 27 |
| Rank | Gap | Impact | Tractability | Under-exploration | Data | Total |
|---|---|---|---|---|---|---|
| 16 | Sleep disruption as a modifiable risk factor — Bidirectional relationship between sleep disorders and tau accumulation; circadian rhythm interventions | 7 | 7 | 6 | 5 | 25 |
| 17 | Blood-brain barrier permeability in tauopathies — Vascular contributors to tau spreading, perivascular drainage, and glymphatic clearance | 7 | 6 | 7 | 5 | 25 |
| 18 | Metabolic dysfunction and tau — How does impaired glucose metabolism, mitochondrial dysfunction, and insulin resistance affect tau pathology? | 7 | 6 | 7 | 4 | 24 |
| 19 | Sex differences in tauopathy presentation — Why do some tauopathies show sex bias? Hormonal influences on tau metabolism and neuroinflammation | 6 | 6 | 7 | 5 | 24 |
| 20 | Tau aggregation nucleation kinetics — Understanding the rate-limiting steps of tau nucleation, elongation, and fragmentation for therapeutic intervention | 7 | 5 | 8 | 4 | 24 |
What would it take to solve this?
Cross-links:
What would it take to solve this?
Cross-links:
What would it take to solve this?
Cross-links:
| Shared Mechanism | Related Diseases | Key References |
|---|---|---|
| 4R tau aggregation | PSP, CBD, PART | Piccinini et al., 2023 |
| 3R tau aggregation | Pick's disease | Kovacs et al., 2022 |
| Mixed 3R/4R | CTE, AD | Kaufman et al., 2023 |
| TDP-43 co-pathology | CBD-FTLD, CTE | Cykowski et al., 2022 |
Tanna et al. Tau PET for differential diagnosis (2024). 2024. ↩︎
Kaufman et al. Tau propagation mechanisms (2023). 2023. ↩︎
Coppola-Savino et al. MAPT mutations and phenotype modifiers (2023). 2023. ↩︎
Alquezar et al. Tau PTM crosstalk (2023). 2023. ↩︎
Soria et al. Anti-tau seeding therapeutics (2024). 2024. ↩︎
Singh et al. Microglia and tau spreading (2024). 2024. ↩︎
McKee et al. CTE staging criteria (2023). 2023. ↩︎
Chin et al. Astrocytes in tauopathy (2024). 2024. ↩︎
Tanzi et al. GWAS in tauopathies (2023). 2023. ↩︎
Alonso et al. Tau phosphorylation site toxicity (2024). 2024. ↩︎